LA Consultants
Life Abundant 1.502.544.5757
Gold Standard of Care

“The MACULA RISK TEAM at LA Consultants is dedicated to reducing the ever-growing epidemic of vision loss throughout the world.  Age-Related Macular (AMD) degeneration is a tremendous threat especially with the increasing aging population in America.  Improvements in the recognition of the early signs of macular degeneration, such as that available through spectral domain digital imaging, provides physicians with advanced retina diagnostic capabilities.  Now Macula Risk® DNA/genetic testing is available.  LA believes that working with the newest genetic technologies affords doctors and patients the opportunity to get the jump on loss of vision in this feared disease.  With a very simple test, the doctor is enabled with knowledge to better assess the risk of severe vision loss associated with AMD and modify the treatment plan appropriately.  This knowledge will allow the doctor to provide careful follow-up and intervention consistent with the risk.  We share your vision of an Optometric Medical Model for patient care.

Questions we are often asked:
  • What is Macula Risk® DNA/genetic testing?
  • What is the AMD Standard of Care?
  • Will the protocol effectively ensure patients receive the best continuity of care?
  • What is the plan to take care of the AMD patient's extended family?
  • How do we bring awareness to our community?
  • How do I join the LA team? Click Here

AMD Risk Levels

There are five risk levels defined using Macula Risk® testing.  Risk levels 3, 4 and 5 represent the 20% of people with drusen who have a higher than average risk for vision loss from AMD.


What difference can you make?

Early detection, diagnosis and treatment lead to better visual outcomes. If you identify the patients most atDavid W Nelson, OD MBA - Vice President of Professional Relations risk of developing vision loss from Advanced AMD, monitoring and treatment can begin before their symptoms progress, enabling you to more effectively manage them and to allow you to achieve the best vision outcome. 

When Macula Risk® is identified before the advanced forms of AMD emerge, lifestyle interventions can be effective. These may include:

  • Use of UV-protective eyewear;
  • Micro eye nutrients included in AREDS eye vitamin therapy;
  • Increased dietary antioxidant consumption (dark green and brightly colored vegetables);
  • Smoking cessation; and
  • Control of blood pressure, cholesterol, and body weight.

Individuals who are aware of their Macula Risk®  level, are more likely to accept these lifestyle interventions. Additionally, individuals who are at increased risk (Macula Risk® Level 3, 4 and 5) may benefit from: 

  • A protocol requiring more frequent eye health examinations;
  • Effective monitoring of the retina using high-resolution images;
  • Foresee ‘at-home’ Amsler Grid testing; and
  • Earlier diagnosis and treatment of ‘wet’ AMD with effective therapies.

The earlier you understand your patients' Macula Risk® , the better your chance of protecting their quality of life.

LA doctors have been facilitating the LA Prevention Program since 2003. The doctors, staffs and LA Consultants have worked as a team to develop the BEST patient care protocols and practice managment systems to ensure practice growth, patient loyalty and community leadership. We are proud to share our systems and patient care protocols at no charge to you. We believe that Optometry is leading the way and shedding a light on AMD and we need your help! Below you will find helpful tools to get you started.

Downloads may take a few minutes. Thank you for your patience.

  LA Practicing Prevention Program© Scripts with the latest additions.

AMD Protocol for Optometry

LivingWater Protocol for Optometry
A New Way of Looking at Retinal Disease


Interesting Articles: Heal the Body and Prevention and Management of Eye Disease


A genetic approach to stratification of risk for age-related macular degeneration Brent Zanke, MD, PhD, FRCPC; Steven Hawken MSc; Ronald Carter PhD; David Chow MD, FRCSC

Macular pigment response to a supplement containing meso-zeaxanthin, lutein and zeaxanthin. Richard A Bone*1, John T Landrum2, Yisi Cao2, Alan N Howard3 and Francesca Alvarez-Calderon2

Augmentation of Macular Pigment Following Supplementation with All Three Macular Carotenoids: An Exploratory Study Eithne E. Connolly1,2, Stephen Beatty1,2, David I. Thurnham3, James Loughman4,Alan N. Howard5,6, Jim Stack2, and John M. Nolan1,2

Studies on the singlet oxygen scavenging mechanism of human macular pigment Binxing Li, Faisal Ahmed, Paul S. Bernstein * Department of Ophthalmology and Visual Sciences, Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT 84132, USA

Werbach M, Nutritional Influences on Illness, 2nd Ed, Third Line Press, Tarzana, CA 1993

lron-Westerlund B, Norrby A, Cataracts, Vitamin E and Selenomethionine, ACTA Optham, April 1988; 237-8.

Gale CR, Hall NF, Phillips DIW, et al, Plasma Antioxidant Vitamins and Carotenoids and Age-Related Cataract, Ophthalmology, November 2001;108(11):1992-1998. 38476

VandenLangenberg GM, Mares-Perlman JA, Klein R, Klein BE, Brady WE, Palta M. Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the Beaver Dam Eye Study. Am J. Epi 149;801-809, 1999

Lebuisson DA, Leroy L, Rigal G. Treatment of senile macular degeneration with Gingko biloba extract. Presse Med 15; 1556-1558, 1986

"A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8," Age-Related Eye Disease Study Research